Comparison of JAK2V617F‐positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology

Publisher： John Wiley & Sons Inc

E-ISSN： 1099-1069|36|1|269-275

ISSN： 0278-0232

Source： Hematological Oncology (Electronic), Vol.36, Iss.1, 2018-02, pp. : 269-275

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Imatinib: JAK2V617F proliferation leading to myelofibrosis: case report

By  

Reactions Weekly, Vol. 1, Iss. 1151, 2007-01 ,pp. : 17-18

Adis International

Access to resources Recommend Favorite

Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 357-359

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ethinylestradiol/drospirenone: Essential thrombocythemia and splanchnic deep vein thrombosis in a patient with the Jak2 Val617Phe mutation: case report

By  

Reactions Weekly, Vol. 1, Iss. 1211, 2008-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Imatinib: Emergence of JAK2V617F clone leading to polycythaemia vera, in an elderly patient?: case report

By  

Reactions Weekly, Vol. 1, Iss. 1315, 2010-01 ,pp. : 26-27

Adis International

Access to resources Recommend Favorite

Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis

By Vaddi Kris   Sarlis Nicholas J   Gupta Vikas  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 16, 2012-11 ,pp. : 2397-2407

Informa Healthcare

Access to resources Recommend Favorite